Earnings results expected in 37 days
Summary
ICY is not paying dividends to its shareholders.
The last earnings report, released on Oct 29, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 11, 2025.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on
XMUN (EUR). Want to track ICY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ICY Chart
FAQ
What Is the INCYTE DL-,001(ICY) Stock Price Today?
The ICY stock price today is €0.00.
What Stock Exchange Does INCYTE DL-,001 Trade On?
INCYTE DL-,001 is listed and trades on the NASDAQ (NGS).
What Is the Stock Symbol for INCYTE DL-,001?
The stock symbol for INCYTE DL-,001 is "ICY".
Does INCYTE DL-,001 Pay Dividends? What's The Current Dividend Yield?
Yes, INCYTE DL-,001 pays dividends and the current yield is 0%.
What Is the INCYTE DL-,001 Market Cap?
As of today, INCYTE DL-,001 does not have a market cap available.
What is INCYTE DL-,001 Earnings Per Share?
The INCYTE DL-,001 EPS is 0.
What Is the Next INCYTE DL-,001 Earnings Date?
INCYTE DL-,001 will release its next earnings report on Feb 11, 2025.
Did INCYTE DL-,001 had any splits?
No, INCYTE DL-,001 has never had a stock split.
INCYTE DL-,001 Profile
| Biotechnology Industry | Healthcare Sector | Mr. Herve Hoppenot CEO | XMUN Exchange | US45337C1027 ISIN |
| United States Country | 2,524 Employees | - Last Dividend | 1 Sep 2000 Last Split | - IPO Date |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Contact Information
Address: 1801 Augustine Cut-Off
Phone: 302 498 6700
Website: https://www.incyte.com
2025 © Marketlog. All Rights Reserved.
